Micro-RNAs as diagnostic or prognostic markers in human epithelial malignancies

1471-2407-11-5001471-2407 Review Micro-RNAs as diagnostic or prognostic markers in human epithelial malignancies HuiAngelaAngela.Hui@uhnres.utoronto.ca HowChristinechristine.how@gmail.com ItoEmmaemma.ito@uhnres.utoronto.ca LiuFei-Feifei-fei.liu@rmp.uhn.on.ca

Ontario Cancer Institute (OCI)/Campbell Family Cancer Research Institute (CFCRI); University Health Network (UHN); Toronto, ON, Canada

Department of Medical Biophysics; University of Toronto; Toronto, ON, Canada

Department of Radiation Oncology; Princess Margaret Hospital; UHN; Toronto, ON, Canada

Department of Radiation Oncology; University of Toronto; Toronto, ON, Canada

BMC Cancer 1471-2407 2011 11 1 500 http://www.biomedcentral.com/1471-2407/11/500 2212879710.1186/1471-2407-11-500 8620113011201130112011 2011Hui et al; licensee BioMed Central Ltd.This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Micro-RNAs (miRs) are important regulators of mRNA and protein expression; the ability of miR expression profilings to distinguish different cancer types and classify their sub-types has been well-described. They also represent a novel biological entity with potential value as tumour biomarkers, which can improve diagnosis, prognosis, and monitoring of treatment response for human cancers. This endeavour has been greatly facilitated by the stability of miRs in formalin-fixed paraffin-embedded (FFPE) tissues, and their detection in circulation. This review will summarize some of the key dysregulated miRs described to date in human epithelial malignancies, and their potential value as molecular bio-markers in FFPE tissues and blood samples. There remain many challenges in this domain, however, with the evolution of different platforms, the complexities of normalizing miR profiling data, and the importance of evaluating sufficiently-powered training and validation cohorts. Nonetheless, well-conducted miR profiling studies should contribute important insights into the molecular aberrations driving human cancer development and progression.

BMC Cancer's 10th anniversary special edition

Introduction

Micro-RNAs (miRs) are important regulators of mRNA and protein expression which play important yet complex roles in human cancers 1 . Their biogenesis and biological networks are complex (Figure 1); they are first synthesized as large RNA precursors, processed in the nucleus into approximately 70 nt pre-miRs, folded into imperfect stem-loop structures, transported to the cytoplasm, whereupon they are incorporated into RISC (RNA-induced silencing complex) (reviewed in 2 ). Cleavage by Argonaute-2, then Dicer, results in an approximately 22-nt mature miR duplex; the "guide" strand is retained within the RISC; the "passenger" strand is degraded. Through the seed region (nt 2 to 8), the miR can then bind to the 3'UTR of target mRNA sequences, preventing protein translation, leading to mRNA degradation. More recently, miRs have also been described to target 5'UTR, and even coding regions of transcripts 3 . The current miRDatabase (http://www.mirbase.org) has catalogued more than 1,300 human sequences. Given their ability to target mRNA with imperfect complementarity, and predicted to regulate the expression of approximately one-third of all human transcripts 4 , miRs are considered to be among the largest class of gene regulators 5 6 .

Figure 1

Micro-RNA biogenesis

Micro-RNA biogenesis. MiR's are synthesized initially as large RNA precursors (pri-miRs), processed in the nucleus by RNAse III Drosha, and DGCR8 into approximately 70 nt pre-miR, which are transported to the cytoplasm by exportin-5, with subsequent cleavage by another RNAse III enzyme Dicer, with its co-factor TRBP, releasing the approximately 22-nt mature dsmiR. MiR's can negatively regulate their targets in one of two major ways, depending on the degree of complementarity to its target. First, and probably most commonly, one strand of this duplex is incorporated into the RNA-induced silencing complex (RISC), then binds with imperfect complementarity to the 3'-UTR (untranslated region) of mRNA targets, preventing protein translation. Alternatively, miRs can bind with perfect complementarity to the ORF (open reading frame) of target mRNA's with subsequent degradation. Recent evidence also indicates miRs can also bind to either promoters, or coding regions of mRNAs as additional mechanisms of regulation.

Multiple mechanisms can mediate miR dysregulations in human cancers, including chromosomal gains or losses 7 , mutations of miR located loci 8 , or epigenetic aberrations 8 . Any misstep in miR biogenesis (Figure 1) can also affect miR expression 9 10 , exemplified by the down-regulation of Drosha and Dicer being associated with worse survival in ovarian, lung, and breast cancers 11 . MiRs can be either over- or under-expressed, functioning as tumour suppressors or oncogenes, depending on their downstream target genes 12 . MiR-15a and miR-16-1 are two of the first described down-regulated miRs in chronic lymphocytic leukemia 13 , both target Bcl-2 14 ; thus their absence inhibits apoptosis. Alternatively, miR-21, one of the most commonly over-expressed miRs in solid malignancies, targets PTEN 15 and pro-apoptotic genes 16 17 ; hence pro-survival signals dominate.

Micro-RNA as bio-markers in epithelial cancers

Biomarkers are biological indicators of disease states, utilized to define tumor subtypes, or assess efficacy of interventions 18 . Useful biomarkers can provide insights into tumorigenesis, and facilitate the development of improved therapies. Some current bio-markers include prostate-specific antigen (PSA) 19 , carcinoembryonic antigen (CEA) 20 , CA125 21 , and α-fetoprotein 22 23 . More recently, the role of mRNA or miRs as cancer biomarkers have also been investigated and developed. The prototype mRNA signature is Oncotype DX, the 21-gene set utilized to predict recurrence risks for patients with breast cancer 24 .

MiR expression profilings could distinguish different cancer types 12 , classify sub-types of prostate or breast cancers 25 , identify the tissue origin of tumors 26 , and facilitate the diagnosis of colon 27 , or lung cancers 28 . MiRs can also predict outcome, such as let-7a 28 and miR-155 29 for lung cancer, and select patients for targeted therapy (for example, breast cancer 30 ). Finally, predictive miR signatures have been reported for several malignancies, such as lung 31 32 33 34 , hepatocellular 35 , esophageal 36 , gastric 37 , prostate 38 cervical 39 , and colon cancers 40 .

Micro-RNAs in FFPE samples

The ability to examine FFPEspecimens, a universally standard histologic processing procedure, allows the expeditious discovery and evaluation of potential biomarkers, given their possible link to clinical databases with mature follow-up. Transcript (mRNA) profiling is technically challenging with FFPE samples due to significant RNA degradation during formalin fixation 41 42 , and continued deterioration with storage over time 43 . In contrast, miRs are not significantly affected by fixation, and can be readily extracted from FFPE samples due to their small sizes (approximately 22 nt in length) and remarkable stability 44 45 . Hence, this greatly enhances the ability to evaluate miRs as cancer biomarkers, leading to a multitude of reports describing miR expressions in many epithelial malignancies, summarized as per anatomical site in Table 1.

Table 1

Micro-RNAs as Diagnostic or Prognostic markers in FFPE Samples

Cancer

Diagnostic miRs

Prognostic miRs

References

Head and Neck Squamous cell carcinoma

miR-16, -20a, -21, -106b, -142-3p, -155, -423, let-7i (up);

miR-10a, -125b, -375 (down)

miR-451 (up)

Breast cancer

miR-21(up); let-7a, miR-145, -205 (down)

miR-21 (up)

miR-21, -155, -191, -196a (up); miR-125b, -221 (down)

Lung cancer

miR-21, -205

miR-16 (up)

Gastrointestinal Cancers

Gastric cancer

miR-106a (up)

miR-31 (down)

miR-10b, -21, -223, -338 (up);

miR-30a-5p,

-126, let-7a (down)

Pancreatic cancer

miR-452, -105, -127, -518a-2, -187, -30a-3p (up)

miR-196a-2 (up)

miR-21, -155 (up)

miR-21, -221, -222, let-7a (up)

miR-200c (down)

Gynecological Cancers

Cervical cancer

miR-9, -200a

Ovarian cancer

miR-223 (up); miR-9 (down)

miR-200a, -200b, -429 (down)

miR-23a, -27a (up)

miR-29b (up)

Prostate cancer

miR-125b (up)

miR-15a, -16 (down)

miR-184 (up); miR-146a (down)

miR-184 (up)

miR-203 (down)

miR-34c (down)

miR-221 (down)

As already mentioned, miR-21 up-regulation is the most commonly observed aberrant miR in human cancers, with oncogenic consequences 46 (Table 1). It was first reported in glioblastoma 16 , but also described for epithelial cancers such as head and neck, breast, colon, lung, prostate, and others 12 44 47 ; often associated with worse outcome 40 . Over-expression of miR-21 has been shown to increase cell proliferation, migration, invasion and survival 48 ; in contrast, suppression of miR-21 induced apoptosis and decreased cell proliferation and invasion 49 .

Mir-155 is another commonly dysregulated miR, wherein the majority of studies report its over-expression associated with tumorigenesis in lymphomas, breast, lung, colon, pancreatic cancers, and others 50 . Aside from these two miRs, there is usually minimal overlap of dysregulated miRs described amongt different studies, even when examining the same cancer type; the same variation as previously observed for mRNA profiling. Perhaps this might relate to multiple redundant "wirings" in human cancers 51 , wherein just as four distinct mRNA profiles can all predict for breast cancer relapse 52 , a similar phenomenon might also apply to miR profiles, although this remains to be definitively proven.

Micro-RNAs in blood samples

There is emerging interest in the investigation of miRs as non-invasive biomarkers in circulating blood. This was first described in B-cell lymphoma, reporting elevated levels of miR-155, -210 and -21 in patients' sera, with miR-21 associating with relapse-free survival 53 . In epithelial cancers, Mitchell et al. first identified tumor-derived miRs in plasma samples, and suggested that variations in miR abundance reflected tumor burden 54 . MiRs have been detected as free miRs in either plasma or serum, or contained within microvesicles such as exosomes; the latter being minute, natural membrane vesicles secreted by a variety of different cell types 55 . In addition to miRs, exosomes also carry intact and functional mRNA 56 , with the probable purpose of transferring information and signals throughout the body 55 . Association of epithelial cancer and exosome miRs was first illustrated in ovarian cancer, wherein tumor-derived miR profiles strongly correlated with levels of peripheral blood-derived exosomal miRs 57 . Similar observations have also been reported for lung cancer 58 59 .

As shown in Table 2, the list of potential blood miR biomarkers is even more diverse than those from tissue studies (Table 1). The greatest degree of overlap was reported for miR-21, miR-196a and miR-210 from four different pancreatic cancer studies 60 61 62 63 . As observed for the tissue studies, miR-21 and miR-155 are also the two most common aberrant miRs in circulation with putative diagnostic and prognostic value (Table 2). However, down-regulation of miR-155 was reported in one serum study of ovarian cancer 64 . There is some controversy surrounding miR-155; the majority of reports suggest an oncogenic role; however, in a lung cancer study, its up-regulation predicted for worse outcome for adenocarcinomas, but improved outcome for squamous cell carcinoma patients 65 . One possible tumor suppression function for miR-155 was demonstrated in miR-155 deficient mice, which appeared to reduce oncogenic translocations generated by activation-induced cytidine deaminase (AICD) 66 . Micro-RNA expression levels in circulation can also relate to hormone receptor status in that estrogen negative breast cancer sera samples had higher levels of miR-21 and miR-10b 67 ; in contrast. miR-155 was detected for progesterone receptor positive patients 68 .

Table 2

Micro-RNAs as Non-invasive Biomarkers in Blood Samples

Cancer

Samples

Diagnostic miRs

Prognostic miRs

References

Head and Neck

Plasma

miR-184 (up)

Squamous cell carcinoma

Plasma

miR-24 (up)

Plasma

miR-31 (up)

Plasma

miR-181 (up)

miR-181 (up) correlated with poor survival, lymph-node metastasis, and vascular invasion

Breast cancer

Serum

miR-155 (up) in PR+ve patients

Plasma

miR-425*(up);

let-7d*(down)

Serum

miR-10b, -34a, -155 (up)

miR-10b, -34a, -155 (up) correlated with metastasis

Serum

miR -21, -106a, -155 (up); miR-126, -199a, -335 (down)

Whole blood

miR-195 (up)

miR-21, -10b (up) in ER -ve patients; let-7a (down) in lymph node +ve patients

Serum

miR-21 (up) correlated with visceral metastasis

Non-small-cell lung carcinoma

Pooled serum

miR-25, -223 (up)

Exosome from plasma

miR-17-3p, -21, -106a, -146, -155, -191, -192, -203, -205, -210, -212, -214 (up)

Pooled serum

miR-486, -30d (up); miR-1, -499 (down) associated with overall survival

100

Serum

miR-10b, -155 (up)

miR-10b (up) associated with lymph node metastasis

101

Vesicles of plasma samples

let-7d, let-7f, miR-223, -383, -192, -30e-5p, -301, -572, -20b, -345 (down)

let-7f, miR-30e-3p (up) associated with poor outcome

Gastrointestinal Cancers

Colorectal cancer

Plasma

miR-17-3p, -92 (up)

102

Plasma

miR-29a, -92a (up)

103

Plasma

miR-221 (up)

miR-221 (up) associated with poor overall survival

104

Esophageal

Serum

miR-10a, -22, -100, -148b, -223, -133a, -127-3p (up)

105

Gastric cancer

Serum

miR-1, -20a, -27a, -34, -423-5p (up)

106

Plasma

miR-17-5p, -21, -106a, -106b (up); let-7a (down)

107

Hepatocellu-lar carcinoma

Serum

miR-500 (up)

108

Serum

miR-1, -25, -92a, -206, -375, -let-7f (up) (HBV-associated); miR-25, -375, and let-7f (up) (HCC detection)

109

Serum

miR-21, -122, -223 (up)

110

Serum

miR-122 (up)

111

Serum

miR-885-5p (up)

112

Serum

miR-16 (down) combined with AFP, AFP DCP increases specificity of HCC detection

113

Pancreatic cancer

Plasma

miR-21, -210, -155, -196a (up)

Plasma

miR-210 (up)

Plasma

miR-21 (up)

Serum

miR-21, -155, -196a (up)

miR-196a (up)

Ovarian cancer

Exosome from serum

miR-21, -141, -200a, -200c, -200b, -203, -205, -214 (up) correlated with stage

Serum

miR-21, -92, -93, -126 -29a (up); miR-155, -127, -99b (down)

Whole blood

miR-30c1* (up); miR -342-3p, -181a*, -450b-5p (down)

114

Prostate cancer

Serum

miR-141 (up)

miR-100, -125b, -141, -143, -296 (up)

Serum

miR-16, -92a, -103, -107, -197, -34b, -328, -485-3p, -486-5p, -92b, -574-3p, -636, -640, -766, -885-5p (up)

115

Serum

miR-20b, -874, -1274a, -1207-5p, -93, -106a (up); miR- 223, -26b, -30c, -24 (down)

miR-24 (down) in metastatic cancers

116

Serum

miR-375, -141 (up)

117

Serum

miR-21 (up)

miR-21 (up) associated with resistant to docetaxel-based chemotherapy

118

Serum

miR-21, -141, -221 (up)

119

In summary, there are multitudes of reports describing the potential value of miRs as both diagnostic and prognostic bio-markers for human malignancies. None to date, however, have been translated into clinical practice, likely a reflection of its complex biology, and lack of validation studies using appropriately-powered sample sizes.

Challenges of Micro-RNA as bio-markers

Despite the promising data supporting the potential value of miRs as biomarkers, many challenges remain. First, robust platforms, as well as appropriate statistical and bio-computational analyses must be utilized in order to identify potential candidate miR signatures for predicting outcome. Furthermore, such candidate signatures must be validated using independent cohorts statistically powered to confirm the existence of a predictive signature. Second, the selection of the appropriate reference controls is extremely important for normalization of biological variation. Recent reports have observed that some of the commonly-utilized reference miRs, such as RNU43, RNU44 or RNU48, in fact fluctuate with the biological entity of interest 69 ; hence it is critical to determine the most stable miRs for each condition under examination. Third, it is conceivable that given the "upstream" effects of miRs, and their biological complexities which we are just starting to unravel, their pattern of expression might be too subtle and variable to serve as robust predictive signatures. Nonetheless, pursuit of investigations such as prognostic signatures, or their measurements in sera/plasma are definitely warranted, particularly when using appropriately-sized population cohorts.

Conclusion

Application of the potential role of miRs as molecular bio-markers in human epithelial malignancies is widely supported by the large number of studies conducted in different cancers. There is great promise that they will aid in the early diagnosis of cancer, and the development of personalized therapies. Further research into miR biogenesis and regulation, along with functional target identifications will definitely lead to an improved understanding of the complex mechanisms underlying human cancer development and progression.

Abbreviations

AICD: activation-induced cytidine deaminase; CEA: carcinoembryonic antigen; FFPE: formalin fixed and paraffin embedded; miRs: micro-RNAs; PSA: prostate-specific antigen; RISC: RNA-induced silencing complex.

Competing interests

FF Liu is a Section Editor for BMC Cancer.

Authors' contributions

AH performed the literature review and prepared the manuscript. CH performed the literature review and participated in manuscript preparation. EI prepared the figure. FL designed and edited the manuscript. All authors read and approved the final manuscript.

MicroRNAs in cancerGarzonRCalinGACroceCMAnnu Rev Med20096016717910.1146/annurev.med.59.053006.10470719630570MicroRNA assassins: factors that regulate the disappearance of miRNAsKaiZSPasquinelliAENat Struct Mol Biol20101751010.1038/nsmb.176220051982The complexities of microRNA regulation: Mirandering around the rulesBrevingKEsquela-KerscherAInt J Biochem Cell Biol2009421316132919800023miRBase: microRNA sequences, targets and gene nomenclatureGriffiths-JonesSGrocockRJvan DongenSBatemanAEnrightAJNucleic Acids Res200634D14014410.1093/nar/gkj112134747416381832Identification of hundreds of conserved and nonconserved human microRNAsBentwichIAvnielAKarovYAharonovRGiladSBaradOBarzilaiAEinatPEinavUMeiriESharonESpectorYBentwichZNat Genet20053776677010.1038/ng159015965474Small non-coding RNAs in animal developmentStefaniGSlackFJNat Rev Mol Cell Biol2008921923010.1038/nrm234718270516MicroRNA signatures in human cancersCalin GA CroceCMNat Rev Cancer2006685786610.1038/nrc199717060945A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemiaCalinGAFerracinMCimminoADi LevaGShimizuMWojcikSEIorioMVVisoneRSeverNIFabbriMIulianoRPalumboTPichiorriFRoldoCGarzonRSevignaniCRassentiLAlderHVoliniaSLiuCGKippsTJNegriniMCroceCMN Engl J Med20053531793180110.1056/NEJMoa05099516251535The role of microRNAs in cancer: no small matterWiemerEAEur J Cancer2007431529154410.1016/j.ejca.2007.04.00217531469microRNAs as oncogenes and tumor suppressorsZhangBPanXCobbGPAndersonTADev Biol200730211210.1016/j.ydbio.2006.08.02816989803Dicer, Drosha, and outcomes in patients with ovarian cancerMerrittWMLinYGHanLYKamatAASpannuthWASchmandtRUrbauerDPennacchioLAChengJFNickAMDeaversMTMourad-ZeidanAWangHMuellerPLenburgMEGrayJWMokSBirrerMJLopez-BeresteinGColemanRLBar-EliMSoodAKN Engl J Med20083592641265010.1056/NEJMoa0803785271098119092150A microRNA expression signature of human solid tumors defines cancer gene targetsVoliniaSCalinGALiuCGAmbsSCimminoAPetroccaFVisoneRIorioMRoldoCFerracinMPrueittRLYanaiharaNLanzaGScarpaAVecchioneANegriniMHarrisCCCroceCMProc Natl Acad Sci USA20061032257226110.1073/pnas.0510565103141371816461460Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemiaCalinGADumitruCDShimizuMBichiRZupoSNochEAldlerHRattanSKeatingMRaiKRassentiLKippsTNegriniMBullrichFCroceCMProc Natl Acad Sci USA200299155241552910.1073/pnas.24260679913775012434020miR-15 and miR-16 induce apoptosis by targeting BCL2CimminoACalinGAFabbriMIorioMVFerracinMShimizuMWojcikSEAqeilanRIZupoSDonoMRassentiLAlderHVoliniaSLiuCGKippsTJNegriniMCroceCMProc Natl Acad Sci USA2005102139441394910.1073/pnas.0506654102123657716166262MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancerMengFHensonRWehbe-JanekHGhoshalKJacobSTPatelTGastroenterology200713364765810.1053/j.gastro.2007.05.02217681183MicroRNA-21 is an antiapoptotic factor in human glioblastoma cellsChanJAKrichevskyAMKosikKSCancer Res2005656029603310.1158/0008-5472.CAN-05-013716024602miR-21-mediated tumor growthSiMLZhuSWuHLuZWuFMoYYOncogene2007262799280310.1038/sj.onc.121008317072344Biomarkers in phase I oncology trials: signal, noise, or expensive distraction?RatainMJGlassmanRHClin Cancer Res2007136545654810.1158/1078-0432.CCR-07-213318006752Biology of prostate-specific antigenBalkSPKoYJBubleyGJJ Clin Oncol20032138339110.1200/JCO.2003.02.08312525533Identification, characterization and utilization of tumor cell selectin ligands in the design of colon cancer diagnosticsThomasSNTongZStebeKJKonstantopoulosKBiorheology20094620722519581728Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centreOsmanNO'LearyNMulcahyEBarrettNWallisFHickeyKGuptaRIr Med J200810124524718990955Early detection of primary hepatocellular carcinoma by screening for alpha-fetoprotein in high-risk families. A case-reportHeywardWLLanierAPBenderTRMcMahonBJKilkennySPaprockiTRKlineKTSilimperiDRMaynardJELancet19832116111626196582Marker half-life analysis as a prognostic tool in testicular cancerLangePHVogelzangNJGoldmanAKennedyBJFraleyEEJ Urol19821287087116183454A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancerPaikSShakSTangGKimCBakerJCroninMBaehnerFLWalkerMGWatsonDParkTHillerWFisherERWickerhamDLBryantJWolmarkNN Engl J Med20043512817282610.1056/NEJMoa04158815591335Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsiesMattieMDBenzCCBowersJSensingerKWongLScottGKFedeleVGinzingerDGettsRHaqqCMol Cancer200652410.1186/1476-4598-5-24156347416784538MicroRNA expression profiles classify human cancersLuJGetzGMiskaEAAlvarez-SaavedraELambJPeckDSweet-CorderoAEbertBLMakRHFerrandoAADowningJRJacksTHorvitzHRGolubTRNature200543583483810.1038/nature0370215944708Reduced accumulation of specific microRNAs in colorectal neoplasiaMichaelMZO'ConnorSMvan Holst PellekaanNGYoungGPJamesRJMol Cancer Res2003188289114573789Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survivalTakamizawaJKonishiHYanagisawaKTomidaSOsadaHEndohHHaranoTYatabeYNaginoMNimuraYMitsudomiTTakahashiTCancer Res2004643753375610.1158/0008-5472.CAN-04-063715172979A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferationHayashitaYOsadaHTatematsuYYamadaHYanagisawaKTomidaSYatabeYKawaharaKSekidoYTakahashiTCancer Res2005659628963210.1158/0008-5472.CAN-05-235216266980ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approachesChenJQRussoJBiochim Biophys Acta20091796162175293735819527773MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCsDuLSchagemanJJIrnovGirardLHammondSMMinnaJDGazdarAFPertsemlidisAJ Exp Clin Cancer Res2010297510.1186/1756-9966-29-75290733920624269MicroRNA classifiers for predicting prognosis of squamous cell lung cancerRaponiMDosseyLJatkoeTWuXChenGFanHBeerDGCancer Res2009695776578310.1158/0008-5472.CAN-09-058719584273Unique microRNA molecular profiles in lung cancer diagnosis and prognosisYanaiharaNCaplenNBowmanESeikeMKumamotoKYiMStephensRMOkamotoAYokotaJTanakaTCalinGALiuCGCroceCMHarrisCCCancer Cell2006918919810.1016/j.ccr.2006.01.02516530703MicroRNA signature predicts survival and relapse in lung cancerYuSLChenHYChangGCChenCYChenHWSinghSChengCLYuCJLeeYCChenHSSuTJChiangCCLiHNHongQSSuHYChenCCChenWJLiuCCChanWKChenWJLiKCChenJJYangPCCancer Cell200813485710.1016/j.ccr.2007.12.00818167339Identification of metastasis-related microRNAs in hepatocellular carcinomaBudhuAJiaHLForguesMLiuCGGoldsteinDLamAZanettiKAYeQHQinLXCroceCMTangZYWangXWHepatology20084789790710.1002/hep.2216018176954Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinomaGuoYChenZZhangLZhouFShiSFengXLiBMengXMaXLuoMShaoKLiNQiuBMitchelsonKChengJHeJCancer Res200868263310.1158/0008-5472.CAN-06-441818172293Survival prediction of gastric cancer by a seven-microRNA signatureLiXZhangYDingJWuKFanDGut20105957958510.1136/gut.2008.17549719951901MicroRNA profile analysis of human prostate cancersTongAWFulghamPJayCChenPKhalilILiuSSenzerNEklundACHanJNemunaitisJCancer Gene Ther20091620621618949015A microRNA expression signature for cervical cancer prognosisHuXSchwarzJKLewisJSJrHuettnerPCRaderJSDeasyJOGrigsbyPWWangXCancer Res2010701441144810.1158/0008-5472.CAN-09-3289284424720124485MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinomaSchetterAJLeungSYSohnJJZanettiKABowmanEDYanaiharaNYuenSTChanTLKwongDLAuGKLiuCGCalinGACroceCMHarrisCCJAMA200829942543610.1001/jama.299.4.425261423718230780The duration of fixation influences the yield of HCV cDNA-PCR products from formalin-fixed, paraffin-embedded liver tissueBrestersDSchipperMEReesinkHWBoeser-NunninkBDCuypersHTJ Virol Methods19944826727210.1016/0166-0934(94)90125-27989443Effect of duration of fixation on quantitative reverse transcription polymerase chain reaction analysesMacabeo-OngMGinzingerDGDekkerNMcMillanARegeziJAWongDTJordanRCMod Pathol20021597998710.1097/01.MP.0000026054.62220.FC12218216Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assayCroninMPhoMDuttaDStephansJCShakSKieferMCEstebanJMBakerJBAm J Pathol2004164354210.1016/S0002-9440(10)63093-3160221114695316Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissuesHuiABShiWBoutrosPCMillerNPintilieMFylesTMcCreadyDWongDGersterKWaldronLJurisicaIPennLZLiuFFLab Invest20098959760610.1038/labinvest.2009.1219290006Microarray-based, high-throughput gene expression profiling of microRNAsNelsonPTBaldwinDAScearceLMOberholtzerJCTobiasJWMourelatosZNat Methods2004115516110.1038/nmeth71715782179miR-21: a small multi-faceted RNAKrichevskyAMGabrielyGJ Cell Mol Med200913395319175699Comprehensive MicroRNA profiling for head and neck squamous cell carcinomasHuiABLenarduzziMKrushelTWaldronLPintilieMShiWPerez-OrdonezBJurisicaIO'SullivanBWaldronJGullanePCummingsBLiuFFClin Cancer Res2010161129113910.1158/1078-0432.CCR-09-216620145181MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 geneLuZLiuMStribinskisVKlingeCMRamosKSColburnNHLiYOncogene2008274373437910.1038/onc.2008.7218372920MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancerAsanganiIARasheedSANikolovaDALeupoldJHColburnNHPostSAllgayerHOncogene2008272128213610.1038/sj.onc.121085617968323BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomasKluiverJPoppemaSde JongDBlokzijlTHarmsGJacobsSKroesenBJvan den BergAJ Pathol200520724324910.1002/path.182516041695Hallmarks of cancer: the next generationHanahanDWeinbergRACell201114464667410.1016/j.cell.2011.02.01321376230Concordance among gene-expression-based predictors for breast cancerFanCOhDSWesselsLWeigeltBNuytenDSNobelABvan't VeerLJPerouCMN Engl J Med200635556056910.1056/NEJMoa05293316899776Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphomaLawrieCHGalSDunlopHMPushkaranBLigginsAPPulfordKBanhamAHPezzellaFBoultwoodJWainscoatJSHattonCSHarrisALBr J Haematol200814167267510.1111/j.1365-2141.2008.07077.x18318758Circulating microRNAs as stable blood-based markers for cancer detectionMitchellPSParkinRKKrohEMFritzBRWymanSKPogosova-AgadjanyanELPetersonANoteboomJO'BriantKCAllenALinDWUrbanNDrescherCWKnudsenBSStirewaltDLGentlemanRVessellaRLNelsonPSMartinDBTewariMProc Natl Acad Sci USA2008105105131051810.1073/pnas.0804549105249247218663219The regulated exocytosis of enlargeosomes is mediated by a SNARE machinery that includes VAMP4CocucciERacchettiGRupnikMMeldolesiJJ Cell Sci20081212983299110.1242/jcs.03202918713833Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cellsValadiHEkstromKBossiosASjostrandMLeeJJLotvallJONat Cell Biol2007965465910.1038/ncb159617486113MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancerTaylorDDGercel-TaylorCGynecol Oncol2008110132110.1016/j.ygyno.2008.04.03318589210Exosomal microRNA: a diagnostic marker for lung cancerRabinowitsGGercel-TaylorCDayJMTaylorDDKloeckerGHClin Lung Cancer200910424610.3816/CLC.2009.n.00619289371Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survivalSilvaJGarcíaVZaballosÁProvencioMLombardíaLAlmonacidLGarcíaJMDominguezGPeñaCDiazRHerreraMVarelaABonillaFEur Respir J20113761762310.1183/09031936.0002961020595154Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancerAliSAlmhannaKChenWPhilipPASarkarFHAm J Transl Res201132847Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosisKongXDuYWangGGaoJGongYLiLZhangZZhuJJingQQinYLiZDig Dis Sci20115660260910.1007/s10620-010-1285-320614181Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic CancerHoASHuangXCaoHChristman-SkiellerCBennewithKLeQTKoongACTransl Oncol20103109113284731820360935MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of diseaseWangJChenJChangPLeBlancALiDAbbruzzesseJLFrazierMLKillaryAMSenSCancer Prev Res (Phila)2009280781310.1158/1940-6207.CAPR-09-0094The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platformResnickKEAlderHHaganJPRichardsonDLCroceCMCohnDEGynecol Oncol2009112555910.1016/j.ygyno.2008.08.03618954897Prognostic impact of MiR-155 in non-small cell lung cancer evaluated by <it>in situ </it>hybridizationDonnemTEkloKBergTSorbyeSWLonvikKAl-SaadSAl-ShibliKAndersenSStenvoldHBremnesRMBusundLTJ Transl Med20119610.1186/1479-5876-9-6302370321219656MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc-Igh translocationDorsettYMcBrideKMJankovicMGazumyanAThaiTHRobbianiDFDi VirgilioMReina San-MartinBHeidkampGSchwickertTAEisenreichTRajewskyKNussenzweigMCImmunity20082863063810.1016/j.immuni.2008.04.002271365618455451Circulating microRNAs as novel minimally invasive biomarkers for breast cancerHeneghanHMMillerNLoweryAJSweeneyKJNewellJKerinMJAnn Surg201025149950510.1097/SLA.0b013e3181cc939f20134314Circulating microRNAs in breast cancer and healthy subjectsZhuWQinWAtasoyUSauterERBMC Res Notes200928910.1186/1756-0500-2-89269482019454029The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosisGeeHEBuffaFMCampsCRamachandranALeekRTaylorMPatilMSheldonHBettsGHomerJWestCRaqoussisJHarrisALBr J Cancer10411681177Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancerSempereLFChristensenMSilahtarogluABakMHeathCVSchwartzGWellsWKauppinenSColeCNCancer Res200767116121162010.1158/0008-5472.CAN-07-501918089790MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosisYanLXHuangXFShaoQHuangMYDengLWuQLZengYXShaoJYRNA2008142348236010.1261/rna.1034808257886518812439Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinomaLebanonyDBenjaminHGiladSEzagouriMDovAAshkenaziKGefenNIzraeliSRechaviGPassHNonakaDLiJSpectorYRosenfeldNChajutACohenDAharonovRMansukhaniMJ Clin Oncol2009272030203710.1200/JCO.2008.19.413419273703Prognostic implications of miR-16 expression levels in resected non-small-cell lung cancerNavarroADiazTGallardoEVinolasNMarradesRMGelBCampayoMQueraABandresEGarcia-FoncillasJRamirezJMonzoMJ Surg Oncol201010341141521400525Detection of miR-106a in gastric carcinoma and its clinical significanceXiaoBGuoJMiaoYJiangZHuanRZhangYLiDZhongJClin Chim Acta20094009710210.1016/j.cca.2008.10.02118996365Down-regulation of miR-31 expression in gastric cancer tissues and its clinical significanceZhangYGuoJLiDXiaoBMiaoYJiangZZhuoHMed Oncol20092768568919598010MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitisBloomstonMFrankelWLPetroccaFVoliniaSAlderHHaganJPLiuCGBhattDTaccioliCCroceCMJAMA20072971901190810.1001/jama.297.17.190117473300MicroRNA miR-155 is a biomarker of early pancreatic neoplasiaHabbeNKoorstraJBMendellJTOfferhausGJRyuJKFeldmannGMullendoreMEGogginsMGHongSMMaitraACancer Biol Ther2009834034610.4161/cbt.8.4.7338269299719106647MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesionsdu RieuMCTorrisaniJSelvesJAl SaatiTSouqueADufresneMTsongalisGJSuriawinataAACarrereNBuscailLCordelierPClin Chem20105660361210.1373/clinchem.2009.13736420093556MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferationYuJOhuchidaKMizumotoKSatoNKayashimaTFujitaHNakataKTanakaMMol Cancer2010916910.1186/1476-4598-9-169290998020579395Potential role of miR-9 and miR-223 in recurrent ovarian cancerLaiosAO'TooleSFlavinRMartinCKellyLRingMFinnSPBarrettCLodaMGleesonND'ArcyTMcGuinnessESheilsOSheppardBO' LearyJMol Cancer200873510.1186/1476-4598-7-35238392518442408A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancerHuXMacdonaldDMHuettnerPCFengZEl NaqaIMSchwarzJKMutchDGGrigsbyPWPowellSNWangXGynecol Oncol200911445746410.1016/j.ygyno.2009.05.02219501389Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patientsEitanRKushnirMLithwick-YanaiGDavidMBHoshenMGlezermanMHodMSabahGRosenwaldSLevaviHGynecol Oncol200911425325910.1016/j.ygyno.2009.04.02419446316miR-29b expression is associated with disease-free survival in patients with ovarian serous carcinomaFlavinRSmythPBarrettCRussellSWenHWeiJLaiosAO'TooleSRingMDenningKLiJAherneSSammaraeDAzizNAAlhadiAFinnSPLodaMBSSheilsOO'LearyJJInt J Gynecol Cancer20091964164710.1111/IGC.0b013e3181a48cf919509563An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cellsShiXBXueLYangJMaAHZhaoJXuMTepperCGEvansCPKungHJdeVere WhiteRWProc Natl Acad Sci USA2007104199831998810.1073/pnas.0706641104214840918056640The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activitiesBonciDCoppolaVMusumeciMAddarioAGiuffridaRMemeoLD'UrsoLPagliucaABiffoniMLabbayeCBartucciMMutoGPeschleCDe MariaRNat Med2008141271127710.1038/nm.188018931683Loss of mir-146a function in hormone-refractory prostate cancerLinSLChiangAChangDYingSYRNA20081441742410.1261/rna.874808224824918174313Regulatory role of miR-203 in prostate cancer progression and metastasisSainiSMajidSYamamuraSTabatabaiZLSuhSOShahryariVChenYDengGTanakaYDahiyaRClin Cancer Res2011175287529810.1158/1078-0432.CCR-10-261921159887miR-34c is downregulated in prostate cancer and exerts tumor suppressive functionsHagmanZLarneOEdsjoABjartellAEhrnstromRAUlmertDLiljaHCederYInt J Cancer20101272768277610.1002/ijc.2526921351256Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrenceSpahnMKneitzSScholzCJStengerNRudigerTStrobelPRiedmillerHKneitzBInt J Cancer201012739440319585579Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongueWongTSLiuXBWongBYNgRWYuenAPWeiWIClin Cancer Res2008142588259210.1158/1078-0432.CCR-07-066618451220miR-24 up-regulation in oral carcinoma: positive association from clinical and <it>in vitro </it>analysisLinSCLiuCJLinJAChiangWFHungPSChangKWOral Oncol20104620420810.1016/j.oraloncology.2009.12.00520138800Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancerLiuCJKaoSYTuHFTsaiMMChangKWLinSCOral Dis20101636036410.1111/j.1601-0825.2009.01646.x20233326miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinomaYangCCHungPSWangPWLiuCJChuTHChengHWLinSCJ Oral Pathol Med20114039740410.1111/j.1600-0714.2010.01003.x21244495A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancerZhaoHShenJMedicoLWangDAmbrosoneCBLiuSPLoS One20105e1373510.1371/journal.pone.0013735296640221060830Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancerRothCRackBMullerVJanniWPantelKSchwarzenbachHBreast Cancer Res201012R9010.1186/bcr2766304642921047409Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumorWangFZhengZGuoJDingXGynecol Oncol201011958659310.1016/j.ygyno.2010.07.02120801493Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage diseaseHeneghanHMMillerNKellyRNewellJKerinMJOncologist20101567368210.1634/theoncologist.2010-010320576643Direct serum assay for microRNA-21 concentrations in early and advanced breast cancerAsagaSKuoCNguyenTTerpenningMGiulianoAEHoonDSClin Chem201157849110.1373/clinchem.2010.15184521036945Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseasesChenXBaYMaLCaiXYinYWangKGuoJZhangYChenJGuoXLiQLiXWangWZhangYWangJJiangXXiangYXuCZhengPZhangJLiRZhangHShangXGongTNingGWangJZenKZhangJZhangCYCell Res200818997100610.1038/cr.2008.28218766170Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancerHuZChenXZhaoYTianTJinGShuYChenYXuLZenKZhangCShenHJ Clin Oncol2010281721172610.1200/JCO.2009.24.934220194856Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancerRothCKasimir-BauerSPantelKSchwarzenbachHMol Oncol2011528129110.1016/j.molonc.2011.02.00221398193Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screeningNgEKChongWWJinHLamEKShinVYYuJPoonTCNgSSSungJJGut2009581375138110.1136/gut.2008.16781719201770Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancerHuangZHuangDNiSPengZShengWDuXInt J Cancer201012711812610.1002/ijc.2500719876917Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expressionPuXXHuangGLGuoHQGuoCCLiHYeSLingSJiangLTianYLinTYJ Gastroenterol Hepatol2010251674168010.1111/j.1440-1746.2010.06417.x20880178Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinomaZhangCWangCChenXYangCLiKWangJDaiJHuZZhouXChenLZhangYLiYQiuHXingJLiangZRenBYangCZenKZhangCYClin Chem2010561871187910.1373/clinchem.2010.14755320943850A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosisLiuRZhangCHuZLiGWangCYangCHuangDChenXZhangHZhuangRDengTLiuHYinJWangSZenKBaYZhangCYEur J Cancer20114778479110.1016/j.ejca.2010.10.02521112772Circulating microRNAs in plasma of patients with gastric cancersTsujiuraMIchikawaDKomatsuSShiozakiATakeshitaHKosugaTKonishiHMorimuraRDeguchiKFujiwaraHOkamotoKOtsujiEBr J Cancer20101021174117910.1038/sj.bjc.6605608285309720234369MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinomaYamamotoYKosakaNTanakaMKoizumiFKanaiYMizutaniTMurakamiYKurodaMMiyajimaAKatoTOchiyaTBiomarkers20091452953810.3109/1354750090315077119863192Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinomaLiLMHuZBZhouZXChenXLiuFYZhangJFShenHBZhangCYZenKCancer Res2010709798980710.1158/0008-5472.CAN-10-100121098710Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitisXuJWuCCheXWangLYuDZhangTHuangLLiHTanWWangCLinDMol Carcinog20115013614210.1002/mc.2071221229610Clinical significance and potential of hepatic microRNA-122 expression in hepatitis CMoritaKTaketomiAShirabeKUmedaKKayashimaHNinomiyaMUchiyamaHSoejimaYMaeharaYLiver Int20113147448410.1111/j.1478-3231.2010.02433.x21199296Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologiesGuiJTianYWenXZhangWZhangPGaoJRunWTianLJiaXGaoYClin Sci (Lond)201112018319310.1042/CS20100297Circulating MicroRNAs as Biomarkers for Hepatocellular CarcinomaQuKZZhangKLiHAfdhalNHAlbitarMJ Clin Gastroenterol20114535536010.1097/MCG.0b013e3181f18ac221278583Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screeningHauslerSFKellerAChandranPAZieglerKZippKHeuerSKrockenbergerMEngelJBHonigASchefflerMDietlJWischhusenJBr J Cancer201010369370010.1038/sj.bjc.6605833293826420683447Detection of cancer with serum miRNAs on an oligonucleotide microarrayLodesMJCaraballoMSuciuDMunroSKumarAAndersonBPLoS One20094e622910.1371/journal.pone.0006229270496319597549Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patientsMoltzahnFOlshenABBaehnerLPeekAFongLStopplerHSimkoJHiltonJFCarrollPBlellochRCancer Res20117155056010.1158/0008-5472.CAN-10-122921098088Circulating miRNAs are correlated with tumor progression in prostate cancerBraseJCJohannesMSchlommTFalthMHaeseASteuberTBeissbarthTKunerRSultmannHInt J Cancer201112860861610.1002/ijc.2537620473869Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapyZhangHLYangLFZhuYYaoXDZhangSLDaiBZhuYPShenYJShiGHYeDWProstate20117132633110.1002/pros.2124620842666Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancerYaman AgaogluFKovancilarMDizdarYDarendelilerEHoldenriederSDalayNGezerUTumour Biol20113258358810.1007/s13277-011-0154-921274675

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2407/11/500/prepub